SOLICITATION NOTICE
B -- CIR1 Mutation Functional Screening
- Notice Date
- 7/31/2015
- Notice Type
- Presolicitation
- NAICS
- 611310
— Colleges, Universities, and Professional Schools
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NIH-NHLBI-CSB-(HG)-2015-201-DLM
- Archive Date
- 8/22/2015
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOSPSIS TO AWARD A PURCHASE ORDER WITHOUT PROVIDING FOR FULL AND OPEN COMPETITION (INCLUDING BRAND-NAME). THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Institute of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute, (NHGRI), intends to negotiate and award a purchase order on a noncompetitive sole source basis to University of Mississippi Medical Center, 2500 North Street, Jackson, Mississippi 39216-4505 to provide CIR1 mutation functional screening Background: The National Institutes of Health (NIH) mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Human Genome Research Institute (NHGRI) mission has expanded to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. The National Institutes of Health Undiagnosed Disease Program (UDP) is a trans-National Institute of Health (NIH) initiative that focuses on the most puzzling medical cases referred to the NIH Clinical Center in Bethesda, MD. Many medical specialties from other NIH research centers and institutes contribute the expertise needed to conduct the program, including endocrinology, immunology, oncology, dermatology, dentistry, cardiology and genetics, among the dozens of participating senior attending physicians. A longstanding medical condition that eludes diagnosis by a referring physician can be considered undiagnosed and may be of interest to this clinical research program. The goals of the UDP include finding accurate diagnoses and discovering new diseases that provide insight into human physiology and genetics. The UDP was established to evaluate participants who have undiagnosed medical conditions. Purpose/Objectives: The purpose of this acquisition is to provide functional screening for a CIR1 mutation and its role in vascular calcification. Specifically, this laboratory supports the research needs of the UDP by collaborating on particular clinically identified new and rare patient disease. The laboratory of Dr. Michael Garrett at the University of Mississippi Medical Center, Department of Pharmacology and Toxicology specializes in the identification and characterization of genes and pathways involved in kidney disease causation and progression. This collaboration will continue to support the UDP to provide functional analysis of suspected gene mutations to determine disease causation in UDP patients. The laboratory of Dr. Michael Garrett and the University of Mississippi has expertise in performing functional analysis of mutations alter the onset and progression of human kidney disease. They use a multidisciplinary approach by using animal models, cell-culture techniques, proteomic techniques, genetic analysis, genomic approaches, and bioinformatics to understand how gene mutations affect normal kidney function and lead to disease. Procurement: • The contractor shall perform CRISPR-Cas-9 to generate vascular smooth muscle cells (VSMC) that solely contain a CIR1 292T>A mutation. • The contractor shall perform RNAseq techniques to analyze systemic gene expression changes in the mutated cells. • The contractor shall examine changes that occur in the Notch-RUXN2-ALP pathway. • The contractor shall employ functional assays including cell proliferation assays, migration assays, apoptosis assays, etc. determine the impact of the CIR1 292T>A mutation has on calcification as compared to wild-type VSMCs. • The contractor shall examine these changes in appropriate patient-derived cells in the same studies. • The Contractor shall provide unique services specific to genes suspected of causing neurological disease to meet the program goals of the UDP. • The Contractor shall supply electronic copies of all reports appropriate for deposition in the UDP process management system and for other collaborations. Period of Performance: August 2015 through August 2016 Place of Performance : The work will be performed at the University of Mississippi Medical Center. REGULATORY AUTHORITY : This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1. A(b) Soliciting from a single source. ADDITIONAL INFORMATION: Industry Classification (NAICS) Code is 611310, Colleges, Universities and Professional Schools and the Small Business Size Standard is $27.5M. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-83 (July 2, 2015). This requirement is under the SAT of $150,000.00. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by August 7, 2015 and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2015-201-DLM, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NIH-NHLBI-CSB-(HG)-2015-201-DLM/listing.html)
- Place of Performance
- Address: Contractor's Location, United States
- Record
- SN03818855-W 20150802/150731234648-efedfbd53c1ebe9caab1f61c62a3a168 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |